Studies on WF-5239, a new potent platelet aggregation inhibitor

Area of Science:

• Mycology
• Pharmacology
• Organic Chemistry

Background:

• WF-5239 is a novel chemical entity isolated from Aspergillus fumigatus.
• The compound's chemical structure is identified as N-[2-cis(4-hydroxyphenyl)ethenyl]formamide (C9H9NO2).
• Initial characterization suggests potential biological activities.

Purpose of the Study:

• To isolate and characterize WF-5239 from Aspergillus fumigatus.
• To evaluate the pharmacological properties of WF-5239, specifically its effects on platelet aggregation and in vivo mortality models.
• To compare the biological activities of WF-5239 with aspirin.

Main Methods:

• Fungal strain identification and cultivation.
• Purification of WF-5239 using solvent extraction and silica gel chromatography.
• Chemical structure elucidation via physico-chemical properties.
• In vitro assessment of anti-platelet aggregation activity (IC50 values).
• In vivo evaluation of mortality reduction in mice challenged with arachidonic acid.
• Comparative analysis with aspirin.

Main Results:

• WF-5239 was successfully isolated and purified from Aspergillus fumigatus.
• The chemical structure was determined to be N-[2-cis(4-hydroxyphenyl)ethenyl]formamide.
• WF-5239 exhibited potent inhibition of rabbit platelet aggregation induced by arachidonic acid (IC50 = 1.25 µg/ml) and collagen (IC50 = 5.0 µg/ml).
• A single dose of WF-5239 (30 mg/kg) significantly reduced mortality in mice exposed to arachidonic acid.
• Biological activities were found to be comparable to aspirin.

Conclusions:

• WF-5239 is a biologically active compound with significant anti-platelet and protective effects.
• The compound's efficacy in reducing platelet aggregation and mortality suggests therapeutic potential.
• Further research into WF-5239's mechanism of action and safety profile is warranted.